Aktienanalyse zu Cellectar Biosciences Inc (CLRB)CLRBCellectar Biosciences Inc

Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Cellectar Biosciences Inc (CLRB) is a good buy right now due to its current price of $2.53, which is significantly below analyst price targets of $10 and $11, indicating potential upside. The company has reported a strong 87.5% overall response rate in its clinical trials, showcasing the efficacy of its treatment, which could lead to accelerated FDA approval. However, the main risk is its net income loss of $6.9 million in Q2 2026, which reflects ongoing financial challenges.